Additional file 2 of Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice

Additional file 2: Supplementary Fig. 2. Chronic treatment with LNK-754 reduces fibrillar Aβ in the brains of 5XFAD mice. Fibrillar plaque cores were assessed by Thiazine Red immunostaining in the cortex and hippocampus in 5-month-old 5XFAD mice chronically treated with vehicle, LNK-754 or lonafarnib. Quantifications are shown of plaque size in the hippocampus (*p = 0.022 between vehicle and LNK-754, ***p = 0.0003 between LNK-754 and lonafarnib) (A) and cortex (B) and of plaque count in the hippocampus (C) and in the cortex (*p = 0.049) (D). Vehicle, n = 11 (5 males, 6 females); LNK-754, n = 10 (4 males, 6 females); lonafarnib n = 10 (4 males, 6 females). Triangles represent males and circles represent females. 1-way ANOVA with Tukey’s post-hoc multiple comparisons test was performed.